STOCK TITAN

Iridex Announces Strategic Investment in the Company

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Positive)
Tags

Iridex (NASDAQ: IRIX) has secured a strategic investment of $10 million from Novel Inspiration International Co., , with an option for an additional $10 million for future growth initiatives. The initial transaction includes $6 million in new Series B Preferred Stock and $4 million in convertible notes, both priced at $2.00 per share equivalent.

The convertible notes have a three-year term with 12% interest, payable quarterly in common stock. Novel has the right to appoint two board members, with William Moore, former CEO and board member, joining the board. The funding will be used to repay existing debt and for general corporate purposes.

The company also announced the appointment of Romeo Dizon as CFO, replacing Interim CFO Fuad Ahmad. This strategic investment aims to enhance Iridex's ability to pursue opportunities in advanced laser-based treatments, particularly following the November 2024 LCD that introduced new limitations for MIGS devices.

Iridex (NASDAQ: IRIX) ha ottenuto un investimento strategico di 10 milioni di dollari da Novel Inspiration International Co., con un'opzione per ulteriori 10 milioni di dollari per iniziative di crescita future. La transazione iniziale include 6 milioni di dollari in nuove azioni privilegiate di Serie B e 4 milioni di dollari in note convertibili, entrambe valutate a 2,00 dollari per azione equivalente.

Le note convertibili hanno un termine di tre anni con un interesse del 12%, pagabile trimestralmente in azioni ordinarie. Novel ha il diritto di nominare due membri del consiglio di amministrazione, con William Moore, ex CEO e membro del consiglio, che si unisce al consiglio. I fondi saranno utilizzati per ripagare debiti esistenti e per scopi aziendali generali.

L'azienda ha anche annunciato la nomina di Romeo Dizon come CFO, che sostituisce il CFO ad interim Fuad Ahmad. Questo investimento strategico mira a migliorare la capacità di Iridex di perseguire opportunità in trattamenti avanzati basati su laser, in particolare dopo il LCD di novembre 2024 che ha introdotto nuove limitazioni per i dispositivi MIGS.

Iridex (NASDAQ: IRIX) ha conseguido una inversión estratégica de 10 millones de dólares de Novel Inspiration International Co., con una opción para otros 10 millones de dólares para futuras iniciativas de crecimiento. La transacción inicial incluye 6 millones de dólares en nuevas acciones preferentes de Serie B y 4 millones de dólares en notas convertibles, ambas a un precio de 2,00 dólares por acción equivalente.

Las notas convertibles tienen un plazo de tres años con un interés del 12%, pagadero trimestralmente en acciones ordinarias. Novel tiene el derecho de nombrar a dos miembros de la junta, con William Moore, ex CEO y miembro de la junta, uniéndose a la misma. Los fondos se utilizarán para pagar deudas existentes y para fines corporativos generales.

La empresa también anunció el nombramiento de Romeo Dizon como CFO, reemplazando al CFO interino Fuad Ahmad. Esta inversión estratégica tiene como objetivo mejorar la capacidad de Iridex para aprovechar oportunidades en tratamientos avanzados basados en láser, especialmente después del LCD de noviembre de 2024 que introdujo nuevas limitaciones para los dispositivos MIGS.

Iridex (NASDAQ: IRIX)는 Novel Inspiration International Co.로부터 1천만 달러의 전략적 투자를 확보했으며, 향후 성장 이니셔티브를 위한 추가 1천만 달러 옵션이 있습니다. 초기 거래에는 600만 달러의 새로운 B 시리즈 우선주와 400만 달러의 전환 사채가 포함되어 있으며, 두 가지 모두 주당 2.00달러로 평가됩니다.

전환 사채는 3년 만기로 12%의 이자를 제공하며, 분기마다 보통주로 지급됩니다. Novel은 이사회에 두 명의 이사를 임명할 권리가 있으며, William Moore가 이사회에 합류합니다. 자금은 기존 부채를 상환하고 일반 기업 용도로 사용될 예정입니다.

회사는 또한 Romeo Dizon을 CFO로 임명했으며, Fuad Ahmad 임시 CFO를 대체합니다. 이 전략적 투자는 Iridex가 MIGS 장치에 대한 새로운 제한을 도입한 2024년 11월 LCD 이후 레이저 기반 치료 기회를 추구할 수 있는 능력을 향상시키는 것을 목표로 하고 있습니다.

Iridex (NASDAQ: IRIX) a obtenu un investissement stratégique de 10 millions de dollars de Novel Inspiration International Co., avec une option pour un investissement supplémentaire de 10 millions de dollars pour des initiatives de croissance futures. La transaction initiale comprend 6 millions de dollars en nouvelles actions privilégiées de série B et 4 millions de dollars en notes convertibles, toutes deux évaluées à 2,00 dollars par action équivalente.

Les notes convertibles ont une durée de trois ans avec un intérêt de 12%, payable trimestriellement en actions ordinaires. Novel a le droit de nommer deux membres du conseil d'administration, William Moore, ancien PDG et membre du conseil, rejoignant le conseil. Les fonds seront utilisés pour rembourser les dettes existantes et pour des fins corporatives générales.

L'entreprise a également annoncé la nomination de Romeo Dizon en tant que CFO, remplaçant le CFO par intérim Fuad Ahmad. Cet investissement stratégique vise à améliorer la capacité d'Iridex à saisir des opportunités dans des traitements avancés basés sur le laser, en particulier après le LCD de novembre 2024 qui a introduit de nouvelles limitations pour les dispositifs MIGS.

Iridex (NASDAQ: IRIX) hat eine strategische Investition in Höhe von 10 Millionen US-Dollar von Novel Inspiration International Co. gesichert, mit einer Option auf weitere 10 Millionen US-Dollar für zukünftige Wachstumsinitiativen. Die ursprüngliche Transaktion umfasst 6 Millionen US-Dollar in neuen Serie-B-Vorzugsaktien und 4 Millionen US-Dollar in wandelbaren Anleihen, beide zu einem Preis von 2,00 US-Dollar pro Aktienäquivalent.

Die wandelbaren Anleihen haben eine Laufzeit von drei Jahren mit 12% Zinsen, die vierteljährlich in Stammaktien zahlbar sind. Novel hat das Recht, zwei Vorstandsmitglieder zu ernennen, wobei William Moore, ehemaliger CEO und Vorstandsmitglied, dem Vorstand beitritt. Die Mittel werden verwendet, um bestehende Schulden zu begleichen und für allgemeine Unternehmenszwecke.

Das Unternehmen gab außerdem die Ernennung von Romeo Dizon zum CFO bekannt, der den interimistischen CFO Fuad Ahmad ersetzt. Diese strategische Investition zielt darauf ab, die Fähigkeit von Iridex zu verbessern, Chancen in fortschrittlichen laserbasierten Behandlungen zu verfolgen, insbesondere nach dem LCD im November 2024, das neue Einschränkungen für MIGS-Geräte einführte.

Positive
  • Secured $10M strategic investment with option for additional $10M
  • Debt refinancing through repayment of existing Senior Convertible Promissory Note
  • Strengthened leadership with appointment of experienced CFO Romeo Dizon
Negative
  • 12% interest rate on convertible notes indicates high cost of capital
  • Potential dilution for existing shareholders through quarterly interest payments in common stock
  • New investor gains significant control with right to appoint two board members

Insights

Iridex's $10 million strategic investment from Novel Inspiration represents a significant recapitalization at a substantial premium to market. The transaction structure—$6 million in Series B Preferred Stock and $4 million in convertible notes—is priced at a $2.00 per share equivalent, nearly 100% above the current $1.01 trading price, signaling strong investor confidence in Iridex's underlying value.

This financing provides important working capital for a company with just $18.1 million market capitalization, while the option for an additional $10 million in "Growth Notes" creates a pathway for future initiatives. However, the 12% interest rate on the convertible notes indicates significant perceived risk, and quarterly interest payments in common stock will create ongoing dilution.

The investment coincides with a potentially favorable shift in the competitive landscape, as the November 2024 Local Coverage Determination has introduced new limitations for competing MIGS devices. This regulatory change could create market opportunities for Iridex's laser-based glaucoma treatments.

Former CEO William Moore's involvement and statement about expanding "beyond the laser therapies that have historically been its focus" signals a potential strategic pivot. With Novel gaining rights to appoint two board members, investors should watch closely for emerging strategic initiatives that could reshape the company's direction and market focus.

MOUNTAIN VIEW, Calif., March 19, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems and delivery devices for the treatment of glaucoma and retinal diseases, today announced the closing of a strategic investment in the company resulting in $10 million of gross proceeds along with an option by the investor to fund up to $10 million of additional proceeds for future growth initiatives (the “Transaction”). The sole counterparty to the Transaction is Novel Inspiration International Co., Ltd. (“Novel”), an investment company founded in 2020, which had the assistance of William Moore, formerly both a board member and Chief Executive Officer of the company.

The portion of the Transaction that closed today involves the sale of $6 million of new Series B Preferred Stock (the “Series B Preferred”) and $4 million in aggregate principal amount of notes convertible into Series B Preferred. Pursuant to the Transaction documents, Iridex and Novel will jointly pursue growth initiatives which may result, at Novel’s election, in the issuance of an additional $10 million in aggregate principal amount of notes (the “Growth Notes”) convertible into common stock of the company.

The Series B Preferred and notes convertible into shares of Series B Preferred issued today were priced at a common stock equivalent of $2.00 per share. The Growth Notes will convert into common stock based upon the company’s future public market common stock trading price, subject to a conversion price floor and escalating future maximum conversion prices. All of the convertible notes have three-year terms and bear interest at 12%, with such interest payable quarterly in the form of common stock, with the number of shares due based upon the company’s future public market common stock trading price, in each case, subject to a conversion price floor and escalating future maximum conversion prices. The terms and conditions of the Series B Preferred, the convertible notes and certain other rights granted to Novel are further defined in the Transaction documents filed as exhibits to the Company’s Form 8-K expected to be filed on the date hereof. Interested parties are encouraged to review the Transaction documents to fully understand the terms of the Transaction, which are summarized herein.

Iridex’s Chief Executive Officer, Patrick Mercer, commented, “The Novel Transaction concludes the strategic review process previously announced by the company. We are excited about our future prospects to collaborate with Novel. This Transaction recapitalizes the company, enhancing our ability to pursue opportunities related to our advanced laser-based treatments, particularly for glaucoma. This is especially important following the November 2024 Local Coverage Determination (LCD), which we believe significantly altered the reimbursement landscape for physicians by introducing new limitations for implantable Micro-Invasive Glaucoma Surgery (MIGS) devices."

In connection with the Transaction, Novel has the right to appoint two board members. William Moore, who will be joining Iridex’s board of directors in connection with the Transaction, commented, “Iridex is a globally known brand with a long history that is highly regarded in the ophthalmology space. I believe Iridex can and should look to leverage these existing assets to expand its business beyond the laser therapies that have historically been its focus. I approached Novel with this idea, and they agreed to provide the financing for the Transaction.”

A portion of the proceeds of the sale and issuance of the Series B Preferred Stock and the initial convertible notes was used for the repayment of the Senior Convertible Promissory Note, dated August 7, 2024, issued by the company to Lind Global Asset Management IX LLC, with the remaining proceeds to be used for general corporate purposes.

Reflecting the conclusion of its strategic review, Iridex is announcing the appointment of Romeo Dizon as the company’s Chief Financial Officer. Mr. Dizon replaces Fuad Ahmad, who had served as Interim Chief Financial Officer. Mr. Dizon previously worked with Iridex from 2008 to 2020, serving at various times as the company’s Controller, Vice President of Finance, and Interim Chief Financial Officer.

Iridex will provide its final fourth quarter and full year 2024 financial results, which will be released and discussed as previously announced, on a conference call scheduled for 2:00pm PT on Thursday, March 27, 2025. That call will focus on the company’s existing operations. A special call will be scheduled for Iridex investors in April 2025, prior to the ASCRS Annual Meeting, which is scheduled for April 25-28 in Los Angeles.

About Iridex Corporation

Iridex Corporation is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. The Company’s proprietary MicroPulse® technology delivers a differentiated treatment that provides safe, effective, and proven treatment for targeted sight-threatening eye conditions. Iridex’s current product line is used for the treatment of glaucoma and diabetic macular edema (DME) and other retinal diseases. Iridex products are sold in the United States through a direct sales force and internationally primarily through a network of independent distributors into more than 100 countries. For further information, visit the Iridex website at www.iridex.com.

MicroPulse® is a registered trademark of Iridex Corporation, Inc. in the United States, Europe and other jurisdictions. © 2025 Iridex Corporation. All rights reserved.

Safe Harbor Statement

This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Act of 1934, as amended, including statements made about the joint pursuit of collaboration initiatives with Novel and the Growth Notes, as well as regarding future opportunities for strategic expansion related to and beyond laser treatments. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These statements are not guarantees of future performance and actual results may differ materially from those described in these forward-looking statements as a result of a number of factors. Please see a detailed description of these and other risks contained in our Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 12, 2024. Forward-looking statements contained in this announcement are made as of this date and will not be updated.

Investor Relations Contact:
Philip Taylor
Gilmartin Group
investors@iridex.com


FAQ

What is the size and structure of Iridex's (IRIX) new strategic investment?

$10M initial investment ($6M Series B Preferred Stock, $4M convertible notes) with option for additional $10M, priced at $2.00 per share equivalent

What are the terms of IRIX's new convertible notes from Novel Inspiration?

3-year term, 12% interest paid quarterly in common stock, with conversion price floor and escalating maximum prices

How will Iridex (IRIX) use the proceeds from the Novel investment?

To repay existing Senior Convertible Promissory Note and for general corporate purposes

What governance changes resulted from Novel's investment in IRIX?

Novel gains right to appoint two board members, with former CEO William Moore joining the board

What strategic focus will IRIX pursue with the new investment?

Enhanced focus on advanced laser-based treatments, particularly for glaucoma, following November 2024 LCD changes affecting MIGS devices
Iridex

NASDAQ:IRIX

IRIX Rankings

IRIX Latest News

IRIX Stock Data

14.97M
13.35M
20.67%
19.45%
1.6%
Medical Devices
Electromedical & Electrotherapeutic Apparatus
Link
United States
MOUNTAIN VIEW